Last reviewed · How we verify
ARD103
At a glance
| Generic name | ARD103 |
|---|---|
| Sponsor | ARCE Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS (PHASE1, PHASE2)
- A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARD103 CI brief — competitive landscape report
- ARD103 updates RSS · CI watch RSS
- ARCE Therapeutics, Inc. portfolio CI